Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8332379 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL343765 | 0.94 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL10335813 | 0.94 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL15152173 | 0.94 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| Ether SCHEMBL9546497 | 0.89 | LMNA (0.38) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL23497303 | 0.88 | LMNA (0.37) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL234252 | 0.85 | LMNA (0.36) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL3127123 | 0.83 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL3651875 | 0.83 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL5496627 | 0.83 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4382603-A1 | ARTIFICIAL NUCLEIC ACID FOR INDUCING SPECIFIC THREE-DIMENSIONAL STRUCTURE | Sophia School Corporation (JP) | 2024-06-12 | — | — | EP | disclosed |
| CN-115176009-A | Methods and compositions for targeting PD-L1 | 安力高医药股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-2781599-B1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2781598-B1 | NUCLEIC ACID MOLECULE FOR INHIBITING ACTIVITY OF RNAI MOLECULE | UNIV OSAKA CITY (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-9873879-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170073683-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2017-03-16 | — | — | US | disclosed |
| US-9540650-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160222386-A1 | NUCLEIC ACID MOLECULE FOR INHIBITING ACTIVITY OF RNAI MOLECULE | OSAKA CITY UNIVERSITY (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2015-04-30 | — | — | US | disclosed |
| US-20150011745-A1 | NUCLEIC ACID MOLECULE FOR INHIBITING ACTIVITY OF RNAI MOLECULE | OSAKA CITY UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| EP-2781599-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | Riken (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781598-A1 | NUCLEIC ACID MOLECULE FOR INHIBITING ACTIVITY OF RNAI MOLECULE | Osaka City University (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20140256794-A1 | ACTIVATION OF FUNCTIONAL NUCLEIC ACID BY SPECIFIC MODIFICATION | RIKEN (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2770054-A1 | ACTIVATION OF FUNCTIONAL NUCLEIC ACID BY SPECIFIC MODIFICATION | Riken (JP) | 2014-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TARBP1, DNTT, FABP1 | LMNA 1973/4885L3MBTL1 1165/4885TDP1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.